Diabetes research and clinical practice · 2026
The landscape of monogenic diabetes in Italy. Comparisons with other European countries.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Di Paola Rosa, Rutigliano Irene, Fini Grazia, Menzaghi Claudia, Mansueto Morena Luce, Piscitelli Pamela, Rampolli Francesca Irene, Salvemini Lucia, Marucci Antonella, Trischitta Vincenzo
Аннотация
AIMS: The information on monogenic diabetes in Italy is sparse, so that disease management relies primarily on data from other European countries, mainly the UK, France and Norway. We describe the largest cohort of Italian patients with monogenic diabetes across wide age-range at diagnosis.
METHODS: In 2017-2025, 521 White unrelated patients with suspected monogenic diabetes underwent NGS and Sanger sequencing. Variants were classified according to gene-specific expert-panel or ClinGen/ACMG guidelines.
RESULTS: Pathogenic/likely-pathogenic variants were found in 127/521 patients (24.4 %). This proportion was inversely related to age at diagnosis, being only 3 % at > 50 years, raising questions about genetic testing in this group. In contrast to what reported in the UK, France and Norway, GCK-diabetes was the most common (54 %) with HNFAs-diabetes, accounting only for 19 % cases. Variants in syndromic diabetes genes explained 22.8 % cases, a proportion similar to that reported in the UK and in France. The MODY probability calculator achieved a much worse discrimination than in the UK where it was developed, highlighting the need of a high-performance algorithm for Italian patients.
CONCLUSIONS: Monogenic diabetes in Italy only partially resembles that in other countries. This information is instrumental to develop a country-specific disease management.
METHODS: In 2017-2025, 521 White unrelated patients with suspected monogenic diabetes underwent NGS and Sanger sequencing. Variants were classified according to gene-specific expert-panel or ClinGen/ACMG guidelines.
RESULTS: Pathogenic/likely-pathogenic variants were found in 127/521 patients (24.4 %). This proportion was inversely related to age at diagnosis, being only 3 % at > 50 years, raising questions about genetic testing in this group. In contrast to what reported in the UK, France and Norway, GCK-diabetes was the most common (54 %) with HNFAs-diabetes, accounting only for 19 % cases. Variants in syndromic diabetes genes explained 22.8 % cases, a proportion similar to that reported in the UK and in France. The MODY probability calculator achieved a much worse discrimination than in the UK where it was developed, highlighting the need of a high-performance algorithm for Italian patients.
CONCLUSIONS: Monogenic diabetes in Italy only partially resembles that in other countries. This information is instrumental to develop a country-specific disease management.